DANIEL HAMSTRA to Antineoplastic Agents, Hormonal
This is a "connection" page, showing publications DANIEL HAMSTRA has written about Antineoplastic Agents, Hormonal.
Connection Strength
1.171
-
Reply to G. Gandaglia et al and K. Lu. J Clin Oncol. 2015 Sep 01; 33(25):2833-4.
Score: 0.429
-
Ageism in the undertreatment of high-risk prostate cancer: how long will clinical practice patterns resist the weight of evidence? J Clin Oncol. 2015 Mar 01; 33(7):676-8.
Score: 0.413
-
Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202. J Clin Oncol. 2019 01 20; 37(3):213-221.
Score: 0.135
-
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. Int J Radiat Oncol Biol Phys. 2015 Oct 01; 93(2):294-302.
Score: 0.107
-
The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Cancer. 2013 Feb 01; 119(3):681-90.
Score: 0.087